DiM: Prognostic Score for Second- or Further-line Immunotherapy in Advanced Non-Small-Cell Lung Cancer: An External Validation.

DiM: Prognostic Score for Second- or Further-line Immunotherapy in Advanced Non-Small-Cell Lung Cancer: An External Validation. Clin Lung Cancer. 2020 09; 21(5):e337-e348.

View in: PubMed

subject areas

Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
Carcinoma, Non-Small-Cell Lung
Carcinoma, Squamous Cell
Female
Follow-Up Studies
Humans
Immunotherapy
Lung Neoplasms
Male
Middle Aged
Prognosis
Retrospective Studies
Survival Rate

authors with profiles

Marina Chiara Garassino